Skip to main content

Ai In Drug Discovery

Basecamp Research Raises $140M to Advance AI-Designed Cell Therapies

Basecamp Research Raises $140M to Advance AI-Designed Cell Therapies

London and Boston – September 24, 2026 -- Basecamp Research has closed a $140 million oversubscribed Series C financing to train new EDEN foundation models and push a pipeline of AI-designed therapeutics toward clinical development.

S32 leads a syndicate spanning NVIDIA, Anthropic-adjacent backers and sovereign funds

The round was led by S32, with participation from NVIDIA, Menlo Ventures' Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures. Andy Conrad, General Partner at S32 and former CEO of Google's Verily, joins Basecamp's Board of Directors.

Inductive Bio Launches Indy, AI Chemistry Agent Beating GPT-5.6, Claude Opus 5

Inductive Bio Launches Indy, AI Chemistry Agent Beating GPT-5.6, Claude Opus 5

NEW YORK – September 17, 2026 -- Inductive Bio has launched Indy, an AI medicinal chemistry agent that scored 89% accuracy on 84 real-program dose-response curves, versus 48% for Claude Opus 5 and 39% for GPT-5.6 Sol run at maximum effort settings.

Indy has doubled chemist productivity inside live partner drug discovery programs

Inductive Bio built Indy internally with its medicinal chemists, computational chemists and DMPK scientists, then deployed it across active partner programs before today's public launch. The company reports the tool doubled team productivity by taking over data QC, SAR analysis, generative chemistry runs, FEP calculation setup and project-update slide generation.